Patterns of Renal Function in Hypertension Due to Unilateral Renal Artery Occlusion

References

• Olin J W., Vidt D G., Gifford R W., Jr, Novick A C. Renovascular diseases in the elderly: an analysis of 50 patients. IACC 1985; 5: 1232–1238
   Google Scholar
• Vidt D G., Eisele G, Gephardt G N., Tubbs R, Novick A C. Atheroembolic renal disease: association with renal arterial stenosis. Cleve Clin J Med 1989; 56: 407–413
   PubMed Web of Science ®Google Scholar
• Bender W, LaFrance N, Walker W G. Mechanism of deterioration in renal function in patients with renovascular hypertension treated with enalapril. Hypertension 1984; 6, (Suppl I):1–193–1–197
   PubMed Web of Science ®Google Scholar
• Huang W C., Plotz D W., Bell P D., Work J, Navar L G. Bilateral renal function responses to converting enzyme inhibitor (SQ 20,881) in two-kidney, one clip Goldblatt hypertensive rats. Hypertension 1981; 3: 285–293
   PubMed Web of Science ®Google Scholar
• Nally J V., Clarke H S., Gupta B K., Gross M L., Low L R., Potvin W J., Windham J P., Grecos G P. Captopril renography in two-kidney and one-kidney Goldblatt hypertension in dogs. J Nucl Med 1987; 28: 1171–1179
   PubMed Web of Science ®Google Scholar
• Masaki Z, Ferrario C M., Bumpus F M. Effects of SQ 20,881 on the intact kidney of dogs with two-kidney, one clip hypertension. Hypertension 1980; 2: 649–656
   PubMed Web of Science ®Google Scholar
• Levenson D J., Dzau V J. Effects of angiotensin-converting enzyme inhibitors on renal hemodynamics in renal artery stenosis. Kidney Internatl 1987; 31: S173–S179, Suppl 20
   Web of Science ®Google Scholar
• Masaki Z, Ferrario C M., Bumpus F M., Bravo E L., Khosla M C. The course of arterial pressure and the effect of Sar1Thr8-angiotensin II in a new model of two-kidney hypertension in conscious dogs. Clin Sci Mol Med 1977; 52: 163–170
   PubMedGoogle Scholar
• Ferrario C M. Contribution of cardiac output and peripheral resistance to experimental renal hypertension. Am J Physiol 1974; 226: 711–717
   PubMed Web of Science ®Google Scholar
• Cushman D W., Wang F L., Fung W C., Grover G J., Harvey C M., Scalese R J., Mitch S L., DeForrest J M. Comparisons in vitro, ex vivo, and in vivo of the action of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989; 28: 115S–130S, Suppl 2
   PubMed Web of Science ®Google Scholar
• Suzuki H, Ferrario C M., Speth R C., Brosnihan K B., Smeby R R., deSilva P. Alteration in plasma and cerebrospinal fluid norepinephrine and angiotensin II during the development of renal hypertension in conscious dogs. Hypertension 1983; 5: I139–I148, Suppl I
   PubMed Web of Science ®Google Scholar
• Suzuki H, Smeby R R., Mikami H, Brosnihan K B., Husain A, DeSilva P, Saruta T, Ferrario C M. Nonrenal factors contribute to plasma cerebrospinal fluid angiotensin II. Hypertension 1986; 8(Suppl I)I95–100
   Google Scholar
• Bridle P A., Brosnihan K B., Speth R C., Goormastic M, Ferrario C M. Basal levels of plasma epinephrine and norepinephrine in the dog. Hypertension 1983; 5(Suppl V)V128–V133
   PubMedGoogle Scholar
• Crofton J T., Share L, Wang B C., Shade R E. Pressor responsiveness to vasopressin in the rat with DOC-salt hypertension. Hypertension 1980; 2: 424–431
   PubMed Web of Science ®Google Scholar
• Scheft P, Novick A C., Stewart B H., Straffon R A. Renal revascularization in patients with total occlusion of the renal artery. J Urol 1980; 124: 184–187
   PubMed Web of Science ®Google Scholar
• Ferrario C M., Helmchen U M., McCubbin J W. On the differences and similarities between the benign and malignant phases of renal hypertension. Recent Advances in Hypertension, P L. Milliez, M Safar. Boehringer Ingelheim, ReimsFrance 1975; Vol. 2.: 159–169
   Google Scholar
• Levens N R. Renal actions of the new angiotensin converting enzyme inhibitor CGS 16,617. Arch Int Pharmacodyn 1988; 292: 266–280
   PubMedGoogle Scholar
• Zimmerman M B., Barclay B W., Lehmann M, Normal J A. Effects of chronic administration angiotensin converting enzyme (ACE) inhibitors on blood pressure and tissue ACE activity in the SHR. Clin Exp Hypertens (Theory and Practice) 1987; 9: 473–476
   PubMed Web of Science ®Google Scholar
• Levens N R., Ksander G M., Zimmerman M B., Mullane K M. Thromboxane synthase inhibition enhances action of converting enzyme inhibitors. Hypertension 1989; 13: 51–62
   PubMed Web of Science ®Google Scholar
• Zimmerman B G., Mommsen C, Kraft C. Renal vasodilatation caused by captopril in conscious normotensive and Goldblatt hypertensive dogs (40896). Proc Soc Exp Biol Med 1980; 164: 459–465
   PubMed Web of Science ®Google Scholar
• Ben L K., Maselli J, Keil L C., Reid I A. Role of renin-angiotensin system in control of vasopressin and ACTH secretons during the development of renal hypertension in dogs. Hypertension 1984; 6: 35–41
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Soto M E., Menard J, Aldiger J C., Corvol P, Milliez P. Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril. Eur J Clin Invest 1981; 11: 449–453
   PubMed Web of Science ®Google Scholar
• Hajj-ali A F., Zimmerman B G. Kinin contribution to renal vasodilator effect of captopril in rabbit. Hypertension 1991; 17: 504–509
   PubMed Web of Science ®Google Scholar
• Ernst C B., Daugherty M E., Kotchen T A. Relationship between collateral development and renin in experimental renal artery stenosis. Surgery 1976; 80: 252–258
   PubMed Web of Science ®Google Scholar
• Huang W C., Ploth D W., Navar L G. Angiotensin-mediated alterations in nephron function in Goldblatt hypertensive rats. Am J Physiol 1982; 243: F553–F560
   PubMed Web of Science ®Google Scholar
• Huang W C., Jackson C A., Navar L G. Nephron responses to converting enzyme inhibition in non-clipped kidney of Goldblatt hypertensive rat at normotensive pressures. Kidney Internatl 1985; 28: 128–134
   PubMed Web of Science ®Google Scholar